11.01.2024 • News

Altana Acquires Effect Pigments Producer Silberline

Global specialty chemicals group Altana has announced to acquire Silberline, a US company that specializes in developing and manufacturing aluminum effect pigments utilized in various applications, ranging from automotive coatings and printing inks to plastics, protective coatings, and packaged consumer goods.

With the move, Altana said it is strategically expanding its Eckart division and strengthening its regional presence, particularly in North America and Asia. “The acquisition is further proof that we are sustainably implementing our strategy of generating value-creating growth through targeted acquisitions,” commented Martin Babilas, CEO of Altana.

Christian Przybyla, president of Eckart, added: “The local research and production capacities of Silberline and Eckart complement each other perfectly. The merger will enhance our ability to respond flexibly to regional customer needs and further optimize our service quality.”

Gary Karnish, CEO of Silberline, said: “The acquisition of Silberline by Eckart creates new potential. Together, we can more intensively drive the development of sustainable product innovations, benefiting both customers and employees.”

Silberline, headquartered in Tamaqua, Pennsylvania, currently employs over 450 people globally. In 2022, the company achieved sales of approximately $80 million.

The completion of the transaction is subject to customary closing conditions, and both parties have agreed not to disclose the purchase price.

Source: Altana
Source: Altana

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read